Close
FINDING CURES TOGETHER<sup>SM</sup>

Hematologic Malignancies: Translating Discoveries to Novel Therapies

Sept. 20-23, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pa.

Conference Chairperson
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.

Conference Co-Chairpersons
Scott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, N.Y.

The AACR is proud to announce a new Special Conference focused on the blood-based cancers and associated disorders categorized as hematologic malignancies and will include presentations pertaining to leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms. This conference will span the spectrum of relevant cancer science and medicine, from basic science discoveries to their translation in the clinic, and will cover those scientific areas that cut across all blood cancers such as genomics, epigenetics, cell death pathways, and the tumor microenvironment, as well as translational and clinical topics such as targetable signaling pathways, drug development, immunotherapy, other treatment modalities, and early clinical trials.

This conference offers a unique opportunity for a lively discussion, in a small setting, of the challenges in the field among basic, translational, and clinical researchers and for potential collaborations among national and international investigators in the field. The chairpersons and members of the Scientific Program Committee for this Special Conference are world-renowned experts in the diverse areas of the field. Under their leadership, the meeting will provide an outstanding forum for the presentation of today’s most exciting developments in the research and treatment of hematologic malignancies. In addition, the major goals of this AACR conference are to highlight the common aspects of both hematologic malignancies and solid tumors and to foster new knowledge and creative ideas about how to treat and cure these diseases.

Scientific Program Committee

  • Julian Adams, Infinity Pharmaceuticals Inc., Cambridge, Mass.
  • John C. Byrd, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
  • Faith Davies, Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom
  • Richard B. Gaynor, Eli Lilly and Company, Indianapolis, Ind.
  • Randy D. Gascoyne, BC Cancer Agency, Vancouver, BC, Canada
  • Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, Tenn.
  • William N. Hait, Janssen Research & Development, Raritan, N.J.
  • Carl H. June, University of Pennsylvania, Philadelphia, Pa.
  • Michelle M. LeBeau, University of Chicago, Chicago, Ill.
  • Jonathan D. Licht, Northwestern University, Chicago, Ill.
  • Crystal L. Mackall, National Cancer Institute, Bethesda, Md.
  • Tak W. Mak, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ont., Canada
  • Elaine R. Mardis, Washington School of Medicine, St. Louis, Mo.
  • Ari M. Melnick, Weill Cornell Medical College, New York, N.Y.
  • Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, Tenn.
  • Kevin M. Shannon, University of California, San Francisco, Calif.
  • Phillip A. Sharp, MIT Koch Institute for Integrative Cancer Research, Cambridge, Mass.

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available

The AACR would like to thank the following organizations for their generous support of this conference.*

Lead Supporter:
Bristol-Myers Squibb

Supporters:
Janssen Research & Development, LLC
The Leukemia & Lymphoma Society

Supporter - Plenary Session 3: Genomics
Penn Medicine

Supporter - Concurrent Session 3: Lymphoma
Lymphoma Research Foundation

Professional Education Grants:
AbbVie, Celgene, Incyte, Pfizer, Seattle Genetics

*as of August 25, 2014